-
Mashup Score: 0Blenrep for multiple myeloma withdrawn from U.S. market - 1 year(s) ago
As requested by the U.S. Food and Drug Administration, the multiple myeloma drug blenrep is being taken off the market after disappointing results in a phase 3 trial.
Source: www.mdedge.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0GSK to stop selling blood cancer drug Blenrep in United States - 1 year(s) ago
GSK will stop selling its blood cancer drug Blenrep in the United States, it said on Tuesday, in another setback for the British drugmaker’s oncology business.
Source: ReutersCategories: Hem/Oncs, Latest HeadlinesTweet-
Unfortunately #blenrep has been pulled from the US treatment landscape for #myeloma due to lack of efficacy in the phase III DREAMM-3 study #mmsm https://t.co/LGiYdnjouG
-
-
Mashup Score: 0The Stem Cell Transplant Daily - 2 year(s) ago
A selection of articles, blog posts, videos and photos recommended by Muzaffar Qazilbash
Source: paper.liCategories: Hem/Oncs, Latest HeadlinesTweet-
The latest The Stem Cell Transplant Daily! https://t.co/NvRw6CBwjF Thanks to @Myeloma_Doc #myeloma #blenrep
-
-
Mashup Score: 0Corneal toxicity associated with belantamab mafodotin is not restricted to the epithelium: neuropathy studied with confocal microscopy - PubMed - 2 year(s) ago
This study is the first to illustrate neurotoxic effects of belamaf on the human cornea.
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
#Myeloma Paper of the Day: Study using confocal microscopy shows corneal toxicity associated with belantamab mafodotin (#BLENREP) may not be restricted to the epithelium, and may also involve subbasal nerve plexus, thereby producing neuropathy: https://t.co/tBELoiC6Gf. #mmsm https://t.co/FnCKq4CgEc
-
-
Mashup Score: 0The Multiple Myeloma Daily - 3 year(s) ago
A selection of articles, blog posts, videos and photos recommended by Robert Z. Orlowski
Source: paper.liCategories: Hem/Oncs, Latest HeadlinesTweet-
The latest The Multiple Myeloma Daily! https://t.co/vWBnqqpl8t #blenrep #ema
-
-
Mashup Score: 0EMA Review of Belantamab Mafodotin (Blenrep) for the Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma - 3 year(s) ago
The Oncologist is committed to helping physicians excel in the constantly changing fields of oncology and hematology through the publication of timely reviews, original studies, and commentaries on important developments.
Source: The OncologistCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
EMA Review of Belantamab Mafodotin (Blenrep) for the Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma #Blenrep #EMA #MultipleMyeloma https://t.co/Yj2ZGHoeUg https://t.co/WZ7uUdjjcl
-
-
Mashup Score: 0Pardon Our Interruption - 4 year(s) ago
As you were browsing www.clinicaloncology.com something about your browser made us think you were a bot. There are a few reasons this might happen: You’re a power user moving through this website with super-human speed. You’ve disabled JavaScript in your web browser. A third-party browser plugin, such…
Source: www.clinicaloncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
.@US_FDA granted accelerated approval to #Blenrep @GSKUS for adults with relapsed or refractory multiple myeloma. https://t.co/7HS4NaPxOE @SagarLonialMD @WinshipAtEmory #FDA #fdapproval #myeloma
-
-
Mashup Score: 0FDA OKs Anti-BCMA Drug for Multiple Myeloma - 4 year(s) ago
Accelerated approval for belantamab mafodotin after four other therapies
Source: www.medpagetoday.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The @US_FDA granted accelerated approval to #Blenrep in heavily pretreated #multiplemyeloma. By @icingram, @MedpageOnco. #MMSM https://t.co/ggQkhkxXWv
-
-
Mashup Score: 1FDA OKs Anti-BCMA Drug for Multiple Myeloma - 4 year(s) ago
Accelerated approval for belantamab mafodotin after four other therapies
Source: www.medpagetoday.comCategories: General Medicine News, Latest HeadlinesTweet-
The @US_FDA granted accelerated approval to #Blenrep in heavily pretreated #multiplemyeloma. By @icingram, @MedpageOnco. #MMSM https://t.co/SMoRKf3nGV
-
-
Mashup Score: 3GSK wins US approval for first-of-its-kind blood cancer drug - 4 year(s) ago
Blenrep is the first multiple myeloma therapy cleared by the FDA that targets BCMA, a protein that’s the focus of high-profile drug development efforts.
Source: BioPharma DiveCategories: Hem/Oncs, Latest HeadlinesTweet-
FDA approves a new kind of blood cancer drug! GSK's #Blenrep--1st of what could soon be several multiple myeloma treatments targeting #BCMA, aka B-cell maturation antigen or CD269 (a TNFR superfamily member), @NedPagliarulo - https://t.co/GIjBvasZUS via @BentheFidler #mmsm
-
#Blenrep for #MultipleMyeloma withdrawn from U.S. market! 👉https://t.co/HoW7Twg25m @ZosiaChustecka @MDedgeHemOnc #BCMA https://t.co/2YBd2HFKyx